PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM
Abstract
Authors
O. Reifsnider A. Kansal J. Franke J. Lee J.T. George M. Brueckmann S. Kaspers S. Brand A. Ustyugova S. Linden N. Hau